Cardiovascular Safety in Postmenopausal Women and Men With Osteoporosis Treated With Denosumab and Zoledronic Acid: A Post‐Authorization Safety Study
Abstract Osteoporosis and cardiovascular disease are common in older adults. Treatment of osteoporosis reduces the burden of debilitating fractures; however, it is important to understand the benefit versus risk of treatment. This study evaluates the risk of stroke (ischemic or hemorrhagic) and myoc...
Main Authors: | Leslie Spangler, Carrie M. Nielson, M. Alan Brookhart, Rohini K. Hernandez, Robert Kees Stad, Tzu‐Chieh Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
Oxford University Press
2023-10-01
|
Series: | JBMR Plus |
Subjects: | |
Online Access: | https://doi.org/10.1002/jbm4.10793 |
Similar Items
-
Potential protective effect of zoledronic acid when switching from long-term therapy of osteoporosis with denosumab
by: O. V. Yakushevskaya
Published: (2021-01-01) -
Pharmacogenetics of Osteoporosis: A Pathway Analysis of the Genetic Influence on the Effects of Antiresorptive Drugs
by: Álvaro del Real, et al.
Published: (2022-04-01) -
Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals
by: Anaïs M J Møller, et al.
Published: (2020-11-01) -
Treatment Consideration in Postmenopausal Osteoporosis Patients at Imminent Fracture Risk
by: Tai Pang Ip
Published: (2022-06-01) -
Assessment and Treatment of Postmenopausal Osteoporosis: An Appraisal of International Guidelines
by: Sumapa Chaiamnuay
Published: (2022-06-01)